Kornimate/medical-research-clean huggingface dataset:
observational study on ckd treatment with a ketosteril supplemented protein-restricted diet (keto-024-cni)

Conditions: Chronic Kidney Disease

Summary: the purpose of this study is to characterize the patient and disease profile under the influence of a protein-restricted diet supplemented with keto acids/amino acids (ka/aa), focusing on the progression of chronic renal insufficiency, calcium and phosphorus metabolism, nutritional status, patient compliance to diet and ketosteril intake as well as the persistent dietary education to ensure compliance in a large group of pre-dialysis patients.


Eligibility criteria:
inclusion criteria: * written informed consent * non-dialyzed patients with ckd * indication for ketosteril according to package insert (pi), including a glomerular filtration rate (gfr) \< 25 ml/min * accepted supplemented protein-restricted diet and newly starting with ketosteril (treatment naïve, i.e., never treated with ketosteril before) * adult patients ≥ 18 years exclusion criteria: * active cancer diseases * pregnancy or breast feeding * hypersensitivity to active substances or to any of the excipients in ketosteril * hypercalcaemia * major disorder of amino acid metabolism, e.g., hereditary diseases * participation in any clinical trial with an investigational drug within 30 days prior to start of study or during the study * illiteracy or incapability to read or write

Keywords: chronic kidney disease, pre-dialytic ketosteril, keto-acids diet, protein-restricted renal function
mayo clinic tapestry 2.0: applying multi-omics for scientific discovery

Conditions: Genetic Predisposition; Exposure, Environmental

Summary: the purpose of this study is to use multi-omics testing on samples collected from mayo clinic patients to build and expand on what has been learned about genomic data.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * registered mayo clinic patient * able to provide informed written consent * able to receive mail and packages within a united states (us) state * able to collect and ship samples within a us state exclusion criteria: * active hematological cancer or history of a hematological cancer * allogeneic bone marrow transplant (e.g., samples from autologous bone marrow transplant recipients are acceptable if collected at least one month after transplant) * other co-morbidity that, in physician's opinion, would interfere with patient's ability to participate in the study (e.g., reduced ability to comprehend, i.e., dementia, intellectual disability, etc.)
evaluation of hdl subfraction changes and hdl-associated enzymes in liver failure patients and healthy donors

Conditions: Liver Failure

Summary: this study aimed to determine high-density lipoprotein (hdl) subfraction profile and hdl-associated enzyme changes in liver failure patients and healthy donors.

objectives: this study aimed to determine high-density lipoprotein (hdl) subfraction profile and hdl-associated enzyme changes in liver failure patients and healthy donors. materials and methods: twenty liver failure patients and twenty healthy donors are selected. blood samples obtained from all patients prior to transplant will analyzed. hdl subfraction analysis will done by continuous disc polyacrylamide gel electrophoresis. plasma levels of apolipoprotein a-1 (apoa-i), cholesteryl ester transfer protein (cetp), and lecithin-cholesterol acyltransferase (lcat) will determined by enzyme-linked immunosorbent assay.

Eligibility criteria:
inclusion criteria: * liver failure patients exclusion criteria: * patients not giving consent * participants who had oncological and hematological diseases, coronary failure, kidney failure, malnutrition, diabetes, traumatic brain injury, or cadaveric lt and who were using psychoactive medicines or having a respiratory system or cns diseases were excluded from the study

Keywords: liver failure hdl subfractions apoa1 cetp lcat
a case series: trumatch graft cage for segmental long bone defects

Conditions: Tibia Fracture; Humerus Fracture; Femoral Fracture; Long Bone Segmental Defect

Summary: this project consists of a prospective case design. study candidates will include all patients ages 18 and over who were evaluated at ucsd and found to have a critical-sized humerus, femur, or tibia segmental defect that would be fixed through surgery. patients who consent to study participation will receive the trumatch graft cage for their long bone segmental defect repair. data on healing rates, complication rates, re-operation rates, time to return to normal activity, and pain levels will be collected for each participation. after 3 years of data collection, we will analyze this data to provide further insight on the utility of the trumatch graft cage. given the significant difficulty with repairing segmental long bone defects, it is imperative to evaluate novel systems to appropriately manage these injuries.


Eligibility criteria:
inclusion criteria: * humerus, femur, or tibia segmental defects requiring surgery * evaluation and treatment at ucsd * ages 18 year and older * abiltiy to understand the content of the patient information/informed consent form exclusion criteria: * any not medically managed severe systemic disease * their doctor has decided that it is in the patient's best interest to receive a different method of repair * their doctor has determined that the patient has a condition that would make them unsuitable for participation in the study * pregnancy or women planning to conceive within the subject participation period (1 year) note: pregnancy will be self-reported and no test will be performed to test for it * prisoner * participation in any other pharmacologic or medicinal product study within the previous month that could influence the results of this study.
a real-world study of biologic therapy for subclinical psoriatic arthritis

Conditions: Subclinical Psoriatic Arthritis

Summary: psoriatic arthritis (psa) is one of the most common comorbidities in patients with psoriasis (pso). current research suggests that the progression from pso to psa can be divided into five stages of the disease: pso, preclinical psa, subclinical psa, prodromal psa, and clinical psa. subclinical psa refers to psoriasis participants who do not exhibit any clinical symptoms of arthritis but show evidence of synovio-enthesitis on ultrasound (us). however, there is currently no definitive biomarker that can accurately predict the progression from pso to psa. synovitis and enthesitis are considered important features of psa. musculoskeletal ultrasound, using b-mode ultrasound and power doppler (pd), can visualize synovitis and enthesitis, allowing for the early detection of subclinical psa, as confirmed by multiple studies. biologics are currently widely used in the treatment of psa, with current treatment interventions primarily focusing on patients already diagnosed with psa. in this study, we conducted a rigorous screening process to identify potential subclinical psa patients among those with moderate to severe psoriasis. we treated these subclinical psa patients with biologics and used musculoskeletal ultrasound as a method of efficacy assessment to observe the improvement of synovitis and enthesitis in subclinical psa patients after 12 weeks of treatment.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosed with moderate to severe plaque psoriasis * no inflammatory arthritis manifestations * psoriasis epidemic severity tool (pest) score ≤ 2 * negative rheumatoid factor * no prior use of any biologic treatments for psoriasis * abnormal findings on musculoskeletal ultrasound screening exclusion criteria: * a previous diagnosis of any other type of arthritis, including rheumatoid arthritis, osteoarthritis, gouty arthritis, ankylosing spondylitis, or similar conditions * patients with contraindications to the use of biologics * pregnant or breastfeeding women, and women of childbearing potential who do not agree to use contraception.

Keywords: synovitis enthesitis
europainclinicsstudy x

Conditions: Back Pain

Summary: non-interventional, retrospective-prospective cohort study based on the collection of data and their evaluation after medical procedures: micro-discectomy, endoscopic discectomy, and hemilaminectomy.

the aim of this clinical study is to compare the benefits and complications after minimally invasive spinal procedures in patients with acute lumbosacral radicular syndrome caused by a herniated disc compressing the spinal neural structures. the study only works with patient data provided by the outpatient clinic for research analysis in the epcs iv clinical study. all patient data are encrypted during collection and evaluation during the study, and stored in an encrypted database. the data will be evaluated by an independent institution - the institute of measurement of the slovak academy of sciences.

Eligibility criteria:
inclusion criteria: * patient age 18-60 years * first spinal surgery in the areas l1-s1 * signed informed consent for the participation in the study exclusion criteria: * patients with a history of other back problems (compression fracture, spondylitis, tumour) * patients after repeated spinal surgeries * patients with a systemic disease affecting the muscles elite athletes * patients who disagree to participate in the study * women with a positive pregnancy test or women planning on becoming pregnant
stroke and anxiety reduction

Conditions: Acute Stroke

Summary: the purpose of this pilot study is to explore the impact that a structured anxiety reduction intervention program has on patients being discharged to home following an acute stroke in an academic medical center. eligible participants will be screened and recruited by the research team through daily rounds. after completing the informed consent process, the research team will pull demographic information from the electronic health record (ehr) and redcap that includes ethnicity and support system. participants will complete the anxiety screen questionnaire (gad-7 anxiety survey) and will be provided with information regarding stroke support groups available with additional nyu langone health and the american heart association internet-based information regarding anxiety reduction (nyu langone health anxiety reduction bundle). the participants will be encouraged to attend a stroke support group for 3 months and utilize the nyu langone health anxiety reduction bundle provided. at the completion of the intervention (3 months), participants will be provided with the gad-7 anxiety survey again and a survey that includes open-ended questions and a program evaluation by email. analysis will occur after final data is collected.


Eligibility criteria:
inclusion criteria: * be diagnosed with an acute stroke * able to speak, read and write in english * not cognitively impaired, as per standard of care documentation in the ehr regarding mental status. * discharged to home * internet access including email * willingness to participate in an anxiety reduction program * length of hospital stay less than 5 days from the initial presentation of stroke symptoms * must be medically stable exclusion criteria: * not diagnosed with an acute stroke * unable to speak, read and write in english as this intervention is not available in other languages and at this time, funding is not available in order to have the resources provided translated or to have translation services available for these participants. * not discharged to home * no internet access including email * unwilling or unable to participate in an anxiety reduction program * cognitively impaired * length of hospital stay greater than 6 days from the initial presentation of stroke symptoms * not medically stable
characteristics and outcomes of patients with covid-19 admitted to the icu

Conditions: SARS-CoV 2; Respiratory Distress Syndrome, Adult; Corona Virus Infection; Critical Illness

Summary: this is a case series of patients with covid-19 admitted to the largest university hospital in sao paulo, brazil, during the 2020 covid-19 pandemic. data will be collected prospectively and retrospectively. the main objective is to describe the characteristics of critically ill patients with covid-19 and their clinical outcomes, and to identify risk factors associated with survival, to inform clinical decision-making and to guide the strategy to mitigate the epidemic, both within each hospital and icu and in public health management.

in december 2019, an outbreak of severe acute respiratory syndrome (sars) attributed to a new coronavirus, called sars-cov-2, was described in the wuhan region of china. this sars, caused by sars-cov-2 was called covid-19, spread across the globe, causing millions of cases on all continents, and thousands of deaths, being characterized as a pandemic. covid-19 is characterized by a flu-like syndrome, with symptoms such as fever, cough, myalgia and gastrointestinal symptoms. most cases are mild, some even asymptomatic, but approximately 15% of patients have more severe presentation, and approximately 5% are critical (7). the acute respiratory failure of critically ill patients with covid-19 has different aspects, including hypoxemia of difficult treatment, associated in some cases with clotting disorders, changes in immunity and inflammatory phenomena that pose challenges for the management of these patients, whose mortality can be high. the hospital das clínicas da faculdade de medicina de são paulo implemented an action plan that provides for the creation of 200 icu beds to serve patients with covid-19. knowing the characteristics of critically ill patients with covid-19 and their clinical outcomes is extremely important to inform clinical decision-making and to guide the strategy to mitigate the epidemic, both within each hospital and icu and in public health management.

Eligibility criteria:
inclusion criteria: * being admitted to one of the covid-19 icus during the study period * suspected or confirmed covid-19 * expected icu stay greater than 24 hours exclusion criteria: * icu readmission during the same hospital stay (patients will be evaluated only during their first icu stay)

Keywords: critical care
clinical evaluation of interstitial laser thermal therapy under continuous mri monitoring as a minimally invasive treatment of patients with medically unbalanced partial epilepsy

Conditions: Drug-resistant Focal Epilepsy; Epilepsy; Epilepsies, Focal; Focal Epilepsy; Drug Resistant

Summary: laser induced interstitial thermal therapy (litt) is a "minimally invasive" procedure that uses the heat generated by a laser light (65°) to destroy brain lesions by coagulation leading to lesion necrosis under real-time mri monitoring. the laser optical fiber is implanted into the lesion using stereotaxy. this technique, which can be performed under local anesthesia and on an outpatient basis, proved its efficacy and safety in the treatment of brain metastases for the first time in the world in 2006 (a. carpentier et al, 2008, 2011). since then, more than 5,000 patients have been treated in the usa, including for epileptogenic lesions (fda device and ce cleared). our goal is to evaluate litt on lesions with drug-resistant epilepsy for which surgical resection is impossible. no therapeutic trial evaluating litt in this indication has been performed to date. it is therefore necessary to study its feasibility and tolerance.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years and \< 80 years 2. patient with a medically unbalanced partial epilepsy 3. patient with a lesional image(s) in morphological mri responsible for epilepsy based on clinical and electrophysiological assessment, +/- pet +/- spect +/- meg +/- seeg 4. patients for whom scheduled neurosurgical treatment with craniotomy appears difficult: deep lesions, eloquent region lesions, patient reluctance to perform surgery. 5. endorsement of the multidisciplinary meeting of neuro-epileptology 6. patient affiliated with a social security scheme 7. patient who has signed prior, free and informed consent exclusion criteria: 1. pharmacosensitive epilepsy 2. patient with poor adherence to medication, or with psychological disorders 3. patients under legal protection 4. patient with a contraindication to mri (metal shards, known allergy to gadolinium, etc.) 5. anticoagulant and antiplatelet therapy underway, cannot be stopped. 6. severe and unbalanced psychiatric disorders 7. pregnant women. women of childbearing age should use oral contraception throughout the study. 8. allergy to local anaesthetics / general anaesthesia
letrozole pretreatment with misoprostol induction of abortion in first trimester missed abortion

Conditions: Missed Abortion

Summary: this study will compare the efficacy of using letrozole pre treatment before misoprostol versus using misoprostol only in the induction of first trimester missed abortion.

intervention type: drug intervention name: letrozole then misoprostol description :letrozole 2.5mg twice per day for 2days then misoprostol 800mcg for all patients to induce abortion arm group label:study group intervention type :drug intervention name:placebo then misoprostol description : placebo for 2days then 800mcg misoprostol to all patients to induce abortion arm group label: control group

Eligibility criteria:
inclusion criteria: 1. maternal age more than 18 years old. 2. gestational age less than 13 weeks confirmed by ultrasound scan on day 1 of the study. 3. hemoglobin \>10 g/dl 4. missed abortion exclusion criteria: 1. mullerian uterine anomalies as septate, bicornuate uterus. 2. fibroid uterus. 3. coagulopathy. 4. medical disorder that contraindicate induction of abortion. 5. allergy to misoprostol or letrozole. -
nicotinamide riboside (nr) to treat moyamoya-like cerebrovascular disease in smooth muscle dysfunction syndrome (smds)

Conditions: Smooth Muscle Dysfunction Syndrome (SMDS)

Summary: the purpose of this study is to determine whether smds patients treated with nr at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if nr treatment results in measurable changes of blood nad+ and nr levels, to determine if aortic measurements are stable after treatment with nr and to evaluate the safety and tolerability of nr in smds patients.


Eligibility criteria:
inclusion criteria: * bodyweight ≥ 12 kg * native (not surgically replaced) ascending aorta * diagnosed with smds with confirmed acta2 mutation disrupting arginine 179 * females with negative urine pregnancy test * must agree to use acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), depo-provera, or an oral contraceptive, for the duration of the study exclusion criteria: * individuals who have undergone surgery to replace aneurysmal or dissected ascending and root aortic tissue with a graft. * additional medical conditions that impair the patient's ability to participate in the study. * known allergy or sensitivity to niacin or nicotinamide riboside. * prior consumption of niacin or nicotinamide riboside supplement within the prior eight weeks. * failure to provide informed consent. * inability to tolerate pet/ct imaging and echocardiography without sedation. * concurrent participation in another intervention trial.

Keywords: smooth muscle aortic alpha-actin (acta2) arginine 179 residue nicotinamide riboside stroke cerebrovascular disease thoracic aortic aneurysms and dissections
bilateral hypoglossal nerve stimulation for treatment of obstructive sleep apnoea with and without complete concentric collapse

Conditions: Obstructive Sleep Apnea

Summary: the objective of this study is to explore the safety and performance of the genio™ system in adult obstructive sleep apnoea (osa) patients with and without complete concentric collapse of the soft palate over a period of 4.5 months of treatment (i.e. 6 months post-surgery) measured by the ahi, at rest to determine if there is a difference in performance between the two populations.

this is a prospective, open-label, multicentric, 2 groups study to assess the safety and performance of the genio™ system in adult obstructive sleep apnoea (osa) patients with and without complete concentric collapse of the soft palate. participants will be consented, enrolled and eligibility criteria checked. if the participant is eligible, participant will proceed with the genio™ is implantation. six (6) weeks after implantation, the implant will be activated and study visits will be scheduled at week 7, month 2, month 3, month 4, month 5 and month 6.

Eligibility criteria:
inclusion criteria: * man or woman between 21 and 75 years of age * body mass index (bmi) ≤ 32 kg/m2 * obstructive apnoea-hypopnea index (ahi) of 15-50 events/hour * participants who have either not tolerated, have failed or refused positive airway pressure (pap) treatments. exclusion criteria: * unable or incapable of providing informed written consent * unwilling or incapable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires
oncoxin® and quality of life in cancer patients

Conditions: Gastric Cancer Stage II; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III; Gastric Cancer Stage III

Summary: it is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain high relative dose intensity of anticancer treatments. food supplement oncoxin (oncx) contains amino acids, vitamins, minerals and biologically active substances of natural origin with high immunostimulatory and antioxidant activity. present study is a real world experience study intended to evaluate the efficacy of oncx in cancer patients.

the study was conducted at 9 centers across the russia and kazakhstan. patients were allocated in 2:1 comparison groups for the oncx and control groups, respectively. a total of 133 patients were enrolled in the study; 84 in the oncx group and 49 as controls. oncx contains microelements, vitamins, amino acids and certain naturally occurring, biologically active substances. it is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain the quality of life in cancer patients.

Eligibility criteria:
inclusion criteria: 1. male and female patients who had signed an informed consent. 2. males and females aged 50-70 y/o 3. gastric cancer iib-iiic, non-small cell lung cancer iib-iiia 4. r0 surgery 5. adjuvant chemotherapy (act) required, 2nd and further course of act, xelox regimen of act for gastric cancer and paclitaxel+carboplatin regimen for non-small cell lung cancer. 6. body mass index (bmi) ≥ 15, serum albumin ≥ 25 g/l. 7. eastern cooperative oncology group performance status ≤ 2 exclusion criteria: 1. severe concomitant diseases or conditions that may complicate or make impossible the patient's participation in the study, or make it difficult to interpret the clinical data (including mental disorders, severe infectious and parasitic diseases and intolerability to any of the oncx components). 2. the patient's family or official relations with a member of staff of the study center. 3. the patient's failure to assess his/her physical and/or emotional condition. 4. the patient's failure to comply with the study requirements. 5. the patient's refusal to participate in the study and pregnancy or lactation.

Keywords: oncoxin nutritional supplement chemotherapy oxidative stress antioxidant